Last reviewed · How we verify
Gaviscon (MAGNESIUM SILICATE)
Gaviscon (generic name: MAGNESIUM SILICATE) is a magnesium silicate drug developed by Sanofi. It is currently FDA-approved (first approved 1983) for Heartburn, Acid Indigestion, Sour Stomach.
Gaviscon is used to treat conditions such as Gastro-esophageal Reflux Disease (GERD) and Dyspepsia. It is a compound sodium alginate oral suspension that works by an unknown mechanism, as its modality is not specified.
At a glance
| Generic name | MAGNESIUM SILICATE |
|---|---|
| Sponsor | Sanofi |
| Drug class | magnesium silicate |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1983 |
Approved indications
- Heartburn
- Acid Indigestion
- Sour Stomach
- Upset Stomach
Common side effects
Key clinical trials
- Clinical Study to Assess Safety, Effectiveness and In-Use Tolerability of Saffron Extract Capsules for Improving Skin Health and Reducing Signs of Aging on Healthy Adult Male and Female Subjects. (NA)
- Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome (PHASE4)
- Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion (PHASE4)
- The Impact of Renalof® Dietary Supplement on Upper Urinary Tract Stone Volume (NA)
- Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions (PHASE3)
- Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma (PHASE1)
- Clinical Trial on the Safety and Efficacy of Magnesium Doped Calcium Silicate 3d Alveolar Bone Repair Unit for Periodontal Bone Defects (EARLY_PHASE1)
- Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gaviscon CI brief — competitive landscape report
- Gaviscon updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Gaviscon
What is Gaviscon?
What is Gaviscon used for?
Who makes Gaviscon?
What is the generic name of Gaviscon?
What drug class is Gaviscon in?
When was Gaviscon approved?
What development phase is Gaviscon in?
Related
- Drug class: All magnesium silicate drugs
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Heartburn
- Indication: Drugs for Acid Indigestion
- Indication: Drugs for Sour Stomach
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing